Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- Trial result
Sarcoma and GIST
Velzatinib (IDRX-42) broad-spectrum KIT/PDGFRA TKI drives 19–44% ORR in advanced GIST (ctDNA VAF ↓>99%)
Velzatinib (IDRX-42; subject to USAN approval) is an oral tyrosine kinase inhibitor designed to cover common primary KIT mutations (exons 9/11) and resistance-associated secondary KIT mutations (exons 13/14/17/18).…
NCT05489237 - Trial result
Myeloproliferative neoplasms
DISC-0974 (anti-hemojuvelin; hepcidin-lowering) drives 50–71% anemia responses in Phase 2 myelofibrosis
DISC-0974 is a first-in-class monoclonal antibody that blocks hemojuvelin (HJV) to suppress BMP-pathway–driven hepcidin and improve iron availability for erythropoiesis. In the US open-label Phase 2 RALLY-MF study…
NCT05320198 - Trial result
Lymphoma
EPCORE NHL-6: SC epcoritamab (CD3×CD20) enables outpatient R/R DLBCL dosing with 64% ORR and 27.2-mo mOS
Epcoritamab is a subcutaneous CD3×CD20 bispecific T-cell engager (already approved in the US for R/R DLBCL) evaluated in the Phase 2 EPCORE NHL-6 outpatient-feasibility study in 2L+ R/R DLBCL across US/Puerto Rico…
NCT05451810 - Trial result
Lymphoma
Epcoritamab (CD20×CD3 bispecific) + R-miniCVP posts 86% CR in frail/anthracycline-ineligible newly diagnosed DLBCL
Epcoritamab is a subcutaneous CD20×CD3 T-cell–engaging bispecific antibody combined here with rituximab–miniCVP (cyclophosphamide/vincristine/prednisone; no anthracycline) in an open-label, single-arm Phase 2 MD…
NCT06045247 - Trial result
Lymphoma
Odronextamab (CD20xCD3 bispecific) + CHOP drives 85% CR in high-risk, untreated DLBCL (OLYMPIA-3 Part 1B)
Odronextamab is an off-the-shelf CD20xCD3 T-cell–engaging bispecific antibody combined here with CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) as first-line therapy in untreated CD20+ DLBCL or high-grade…
NCT06091865 - Trial result Spotlight
Pancreatic cancer
Atebimetinib (MEK deep cyclic inhibitor) + mGnP Delivers 42% ORR in 1L Metastatic PDAC
Atebimetinib is an oral next-generation MEK “deep cyclic inhibitor” (DCI) designed for pulsatile MAPK-pathway inhibition, and was combined with modified gemcitabine/nab-paclitaxel (mGnP; every-other-week dosing) in a…
NCT05585320 - Trial result Spotlight
Pancreatic cancer
Nesuparib (JPI-547) dual TNKS/PARP inhibitor + GemAbraxane hits 53.8% ORR in 1L advanced PDAC, but mFOLFIRINOX combo not tolerated
Nesuparib is an oral dual tankyrase (TNKS) and PARP inhibitor designed to induce “BRCAness” (via WNT/Hippo pathway modulation) and was combined with first-line GemAbraxane or modified FOLFIRINOX in a multicenter,…
NCT05257993 - Trial result Spotlight
Pancreatic cancer
Surufatinib (VEGFR/FGFR1/CSF1R TKI) + KN046 (PD-L1/CTLA-4 bispecific) + gem/nab-paclitaxel drives 71% ORR and 18.0-mo mOS in 1L advanced PDAC
Surufatinib is an oral multi-kinase inhibitor (VEGFR/FGFR1/CSF1R) with anti-angiogenic and macrophage-modulating activity, and KN046 is an IV PD-L1/CTLA-4 bispecific antibody designed to deliver dual checkpoint…
NCT05832892 - Trial result
Pancreatic cancer
Emavusertib (CA-4948) IRAK4/NF-κB Inhibitor + Gem/Nab-Paclitaxel Posts 20% ORR in 2L PDAC (Phase I)
Emavusertib (CA-4948) is an oral IRAK4 inhibitor designed to blunt pro-survival NF-κB signaling and potentially sensitize PDAC to cytotoxic chemotherapy; it is being dose-escalated with gemcitabine/nab-paclitaxel…
NCT05685602 - Trial result
Pancreatic cancer
NP137 (anti–netrin-1; EMT inhibitor) + mFOLFIRINOX Delivers 10.9-mo mPFS in 1L Locally Advanced PDAC
NP137 is a monoclonal antibody that neutralizes netrin-1 to inhibit epithelial-to-mesenchymal transition (EMT), combined here with modified FOLFIRINOX as first-line therapy in LAPNET-01, a single-arm Phase Ib study…
NCT06203821 - Trial result
Pancreatic cancer
Claude Opus 4.1 CA-EDA flags prior neurotoxic chemo as a pain-response predictor in celiac plexus radiosurgery
Conversational AI-assisted exploratory data analysis (CA-EDA) used three commercial LLMs (Claude Opus 4.1, ChatGPT 5.2, Gemini 3 Pro) to analyze raw individual patient data from a completed multicentre single-arm…
NCT03323489 - Trial result
Pancreatic cancer
Ibrilatazar (ABTL0812) autophagy inducer fails ITT PFS but trends to longer OS in ECOG 0 mPDAC
Ibrilatazar (ABTL0812) is a first-in-class oral agent designed to induce cytotoxic autophagy selectively in cancer cells; PanC-ASAP randomized first-line metastatic PDAC patients to ibrilatazar (1300mg TID) +…
NCT04431258 - Trial result
Pancreatic cancer
Olaparib + PD-1 blockade (pembrolizumab) misses PFS bar in gBRCA metastatic PDAC maintenance
SWOG S2001 (NCT04548752) randomized Phase II tested maintenance olaparib (PARP inhibitor) 300mg BID plus pembrolizumab (PD-1) Q3W vs olaparib alone in metastatic pancreatic ductal adenocarcinoma with germline BRCA1/2…
NCT04548752 - Trial result
Pancreatic cancer
Precemtabart tocentecan (M9140) anti-CEACAM5 TOP1 ADC posts 21.7% PR rate in pretreated mPDAC
Precemtabart tocentecan (Precem‑TcT, M9140) is an anti‑CEACAM5 antibody–drug conjugate delivering an exatecan (TOP1 inhibitor) payload; interim data come from the Phase 1b/2 open-label PROCEADE‑PanTumor PDAC substudy…
NCT06710132 - Trial result
Pancreatic cancer
MultiDom telemonitoring (circadian rhythm + ePRO) cuts emergency admissions to 3.8% during upfront mFOLFIRINOX in advanced PDAC
MultiDom (NCT04263948) is a prospective, multicentre, single-arm digital intervention layering continuous chest-sensor circadian monitoring (dichotomy index I<O), daily connected weight, and MDASI-based ePROs to…
NCT04263948 - Trial result
Pancreatic cancer
HCQ (autophagy inhibitor) + CPC (AKT/EMT-modulating repurposed agent) added to mFOLFIRINOX delivers 39% ORR in 1L advanced PDAC
Hydroxychloroquine (HCQ), a lysosomotropic autophagy inhibitor, and chlorphenesin carbamate (CPC), a repurposed agent proposed to blunt AKT-mediated EMT, were combined with first-line modified FOLFIRINOX in a…
NCT05083780 - Trial result Spotlight
Small cell lung cancer
ABBV-706 (SEZ6-targeted topo-1 ADC) posts 52% ORR and 11.3-mo OS in R/R SCLC; combo with budigalimab looks feasible
ABBV-706 is a seizure-related 6 homolog (SEZ6)-targeting antibody–drug conjugate delivering a topoisomerase-1 inhibitor payload; this Phase 1 study (NCT05599984) tested ABBV-706 Q3W as monotherapy (N=124; 65% had ≥2…
NCT05599984 - Trial result
Small cell lung cancer
LB2102 (DLL3-targeted, dnTGFBR2-armored autologous CAR-T) shows early signals in R/R SCLC/LCNEC with manageable CRS/ICANS
LB2102 is an autologous DLL3-directed CAR-T cell therapy armored with a dominant-negative TGF-β receptor 2 (dnTGFBR2) to blunt TGF-β–mediated immunosuppression, evaluated in an open-label, multicenter Phase 1 i3+3…
NCT05680922 - Trial result
Small cell lung cancer
Obrixtamig DLL3×CD3 Adds 73% ORR to 1L ES-SCLC Chemo-IO
Obrixtamig (BI 764532) is an IV DLL3/CD3 IgG-like T-cell engager combined with carboplatin/etoposide/atezolizumab induction followed by obrixtamig plus atezolizumab maintenance in the Phase 1 DAREON-8 trial…
NCT06077500 - Trial result
Stomach and esophageal cancer
Avelumab (anti–PD-L1) + modified DCF perioperative chemo delivers 61% 5-year OS in locally advanced GEA
Avelumab, a PD-L1 checkpoint inhibitor, was combined with perioperative modified DCF (docetaxel/cisplatin/5-FU) in a single-arm Phase II study in locally advanced gastro-esophageal adenocarcinoma (cT3–4 and/or N+, PS…
NCT03288350 - Trial result
Stomach and esophageal cancer
Durvalumab (PD-L1) + CROSS boosts MPR to 54% in resectable esophageal adenocarcinoma; tremelimumab (CTLA-4) adds toxicity without benefit
Durvalumab is an anti–PD-L1 antibody, and tremelimumab is an anti–CTLA-4 antibody; in the Phase II RICE trial (NCT04159974), 56 patients with locally advanced, non-metastatic esophageal adenocarcinoma (≥uT3/Nx or…
NCT04159974 - Trial result
Lymphoma
AZD3470 (MTA-cooperative PRMT5 inhibitor) hits 80% ORR/50% CR in MTAP-deficient r/r cHL (Phase 1)
AZD3470 is an oral, MTA-cooperative PRMT5 inhibitor designed to preferentially engage PRMT5 in MTAP-deficient tumor cells; in this first-in-human Phase 1 PRIMAVERA dose-escalation study (NCT06137144), adults with…
NCT06137144 - Trial result
Cervical and other gynecologic cancers
Camrelizumab (PD-1) + cisplatin/nab-paclitaxel hits 100% ORR and 30% pCR in PD-L1–negative LACC
Camrelizumab is an anti–PD-1 antibody tested here as neoadjuvant chemo-immunotherapy (NACI) with cisplatin + nab-paclitaxel in a multicenter, open-label, single-arm Phase 2 trial in treatment-naïve, PD-L1–negative…
NCT06288360 - Trial result
Head and neck cancer
Adebrelimab (anti–PD-L1) + cisplatin/docetaxel delivers 64% path response rate in stage IVB OSCC
Adebrelimab is an anti–PD-L1 IgG4 checkpoint inhibitor combined here with platinum–taxane chemotherapy (cisplatin + docetaxel) as 2-cycle neoadjuvant immunochemotherapy in a prospective, single-arm Phase II…
NCT06277791 - Trial result
Sarcoma and GIST
Gemcitabine + nab-sirolimus (albumin-bound mTOR inhibitor) delivers 30% ORR in advanced LMS with TSC1/2 alterations
Gemcitabine (antimetabolite chemotherapy) was combined with nab-sirolimus (nab-S; nanoparticle albumin-bound sirolimus, an IV mTORC1 inhibitor designed for higher intratumoral exposure) in an investigator-initiated,…
- Trial result
Lung cancer
Larotrectinib (TRK inhibitor) delivers 69% ORR and ~19-mo PFS in NTRK fusion lung cancer
Larotrectinib is a first-in-class, highly selective, CNS-active TRK (NTRK1/2/3) tyrosine kinase inhibitor evaluated in an updated pooled subset from two clinical trials (NCT02122913; Phase I/II NAVIGATE, NCT02576431)…
NCT02122913 - Trial result Spotlight
Thyroid cancer
Pralsetinib (selective RET inhibitor) drives 92% ORR in pretreated RET fusion+ thyroid cancer; 68% ORR in RET-altered MTC
Pralsetinib is an oral, potent, selective RET tyrosine kinase inhibitor evaluated in the Phase 1/2 ARROW study (NCT03037385) in advanced/metastatic RET-altered thyroid cancer and medullary thyroid cancer (MTC). At…
NCT03037385 - Trial result
Thyroid cancer
THYRO-RT Finds No Significant LRR Benefit From Adjuvant EBRT in High-Risk Thyroid Cancer
THYRO-RT (NCT03669432) randomized patients with high-risk resected non-medullary, non-anaplastic thyroid cancer to surgery plus RAI versus surgery plus RAI and adjuvant EBRT (60 Gy/30 fractions). The cohort was very…
NCT03669432 - Trial result
Acute myeloid leukemia and MDS
Luspatercept (TGF-β superfamily ligand trap) extends transfusion-independence vs epoetin alfa in ESA‑naive LR‑MDS; OS still trending better
Luspatercept (LUSPA), a recombinant fusion protein that binds select TGF-β superfamily ligands to promote late-stage erythroid maturation, was compared with epoetin alfa (EA; an ESA) in the Phase 3, open-label…
NCT03682536 - Trial result
Brain and CNS tumors
Preoperative single-fraction SRS (≈16Gy) for resectable brain mets delivers ~82% 1-year local control with ~5% LMD in meta-analysis
Single-fraction preoperative stereotactic radiosurgery (SRS)—a high-dose, highly conformal radiation treatment delivered to an *intact* resectable brain metastasis immediately before planned surgery—was evaluated in…
NCT05341739
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.